JP7167041B2 - 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体 - Google Patents

免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体 Download PDF

Info

Publication number
JP7167041B2
JP7167041B2 JP2019543051A JP2019543051A JP7167041B2 JP 7167041 B2 JP7167041 B2 JP 7167041B2 JP 2019543051 A JP2019543051 A JP 2019543051A JP 2019543051 A JP2019543051 A JP 2019543051A JP 7167041 B2 JP7167041 B2 JP 7167041B2
Authority
JP
Japan
Prior art keywords
antibody
lag3
antigen
tumor
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019543051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507571A5 (cg-RX-API-DMAC7.html
JP2020507571A (ja
Inventor
マーカス ケリー，
ダンシェ マ，
ウィリアム オルソン，
リチャード タヴァレ，
ギャビン サーストン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61244834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7167041(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020507571A publication Critical patent/JP2020507571A/ja
Publication of JP2020507571A5 publication Critical patent/JP2020507571A5/ja
Application granted granted Critical
Publication of JP7167041B2 publication Critical patent/JP7167041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2019543051A 2017-02-10 2018-02-09 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体 Active JP7167041B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457287P 2017-02-10 2017-02-10
US62/457,287 2017-02-10
PCT/US2018/017525 WO2018148476A1 (en) 2017-02-10 2018-02-09 Radiolabeled anti-lag3 antibodies for immuno-pet imaging

Publications (3)

Publication Number Publication Date
JP2020507571A JP2020507571A (ja) 2020-03-12
JP2020507571A5 JP2020507571A5 (cg-RX-API-DMAC7.html) 2021-03-25
JP7167041B2 true JP7167041B2 (ja) 2022-11-08

Family

ID=61244834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019543051A Active JP7167041B2 (ja) 2017-02-10 2018-02-09 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体

Country Status (18)

Country Link
US (3) US10905784B2 (cg-RX-API-DMAC7.html)
EP (1) EP3580238A1 (cg-RX-API-DMAC7.html)
JP (1) JP7167041B2 (cg-RX-API-DMAC7.html)
KR (2) KR102813603B1 (cg-RX-API-DMAC7.html)
CN (2) CN110650974B (cg-RX-API-DMAC7.html)
AU (2) AU2018219909B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019016336A2 (cg-RX-API-DMAC7.html)
CA (1) CA3053348A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002264A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019008675A2 (cg-RX-API-DMAC7.html)
EA (1) EA201991673A1 (cg-RX-API-DMAC7.html)
IL (2) IL313695A (cg-RX-API-DMAC7.html)
MA (2) MA47456A (cg-RX-API-DMAC7.html)
MX (2) MX2019009565A (cg-RX-API-DMAC7.html)
MY (1) MY200034A (cg-RX-API-DMAC7.html)
PH (1) PH12019501837A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907208XA (cg-RX-API-DMAC7.html)
WO (1) WO2018148476A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
IL322104A (en) 2017-05-30 2025-09-01 Bristol Myers Squibb Co Treatment of lag-3 positive tumors
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
PH12021552675A1 (en) 2019-05-13 2022-07-04 Regeneron Pharma Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20220152555A (ko) * 2020-03-12 2022-11-16 비온드 바이오로직스 엘티디 증가된 안정성을 가진 쉐딩 차단제
PE20230839A1 (es) 2020-06-22 2023-05-19 Ngm Biopharmaceuticals Inc Agentes de union a lair-1 y metodos para su uso
US12447218B1 (en) * 2021-02-09 2025-10-21 Actinium Pharmaceuticals, Inc. Radioconjugates directed to MHC-complexed antigens in cancer
CN115337413B (zh) * 2022-08-08 2023-08-22 中国科学院近代物理研究所 一种针对非小细胞肺癌诊断的放射性分子探针的制备及应用
KR102759386B1 (ko) * 2022-08-11 2025-01-24 성균관대학교산학협력단 89Zr 표지된 항-CD25 항체를 이용한 immuno-PET
US20240299601A1 (en) 2023-02-17 2024-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
CN121127264A (zh) 2023-03-13 2025-12-12 瑞泽恩制药公司 用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合
TW202535926A (zh) * 2023-10-30 2025-09-16 美商再生元醫藥公司 穩定抗體配製物
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
KR100257466B1 (ko) 1994-05-06 2000-07-01 레지날드 쇼트버그 에스. 안토니우스-소도 Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체
WO1997003695A1 (en) 1995-07-21 1997-02-06 Applied Research Systems Ars Holding N.V. Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
US6524802B1 (en) * 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1897548B2 (en) 2003-02-28 2024-05-22 The Johns Hopkins University T cell regulation
US7199064B2 (en) 2003-09-08 2007-04-03 Matsushita Electric Industrial Co., Ltd. Plasma processing method and apparatus
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006049599A1 (en) 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy for atheromatous plaques using immune modulation
US20080260650A1 (en) 2004-10-28 2008-10-23 The General Hospital Corporation Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
WO2008124467A1 (en) 2007-04-06 2008-10-16 Macrocyclics Bifunctional hydroxamic acid ligands and method of synthesis
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US20090297439A1 (en) 2008-06-02 2009-12-03 Metheresis Translational Research Sa, Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20120027055A (ko) 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
KR20140014116A (ko) 2010-12-20 2014-02-05 제넨테크, 인크. 항-메소텔린 항체 및 면역접합체
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
US10668162B2 (en) 2012-01-06 2020-06-02 Linxis B.V. Method for preparing cell targeting conjugates, and the complexes obtained
WO2013138696A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zirconium-89 complexes, methods of labeling cells, labeled cells, kits, and methods of use thereof
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
JP6242865B2 (ja) 2012-05-01 2017-12-06 ジェネンテック， インコーポレイテッド 抗ｐｍｅｌ１７抗体および免疫複合体
KR101718200B1 (ko) 2012-05-21 2017-03-21 제넨테크, 인크. 항-Ly6E 항체 및 면역접합체 및 사용 방법
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US20150191543A1 (en) 2012-08-06 2015-07-09 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014066733A2 (en) 2012-10-25 2014-05-01 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
ES2673583T3 (es) 2013-02-28 2018-06-22 National Cancer Center Anticuerpo contra fibrina insoluble
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
WO2014159087A1 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
EP2970474B1 (en) 2013-03-14 2017-12-20 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
IL240838B (en) * 2013-03-15 2022-09-01 Glaxosmithkline Ip Dev Ltd Anti-3–lag binding proteins
WO2014200969A2 (en) 2013-06-10 2014-12-18 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
HUE056325T2 (hu) 2013-08-26 2022-02-28 Biontech Res And Development Inc SIALYL-LEWIS A elleni humán antitesteket kódoló nukleinsavak
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN105658237B (zh) 2013-10-21 2021-03-09 基因泰克公司 抗Ly6E抗体及使用方法
KR102894975B1 (ko) 2013-11-19 2025-12-04 프레닥스 에이비 인간화된 안티 칼리크레인-2 항체
MA39095A1 (fr) 2013-12-13 2018-08-31 Genentech Inc Anticorps et immunoconjugués anti-cd33
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
MA39313B1 (fr) * 2014-03-11 2018-12-31 Regeneron Pharma Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
WO2015140212A1 (en) 2014-03-19 2015-09-24 Universität Zürich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
WO2015179658A2 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
WO2015188934A1 (en) 2014-06-10 2015-12-17 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
WO2015191715A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
PL3177640T3 (pl) 2014-08-08 2020-11-02 The Board Of Trustees Of The Leland Stanford Junior University Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
TW201625690A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｃｌｌ－１抗體及免疫結合物
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
KR102508173B1 (ko) 2014-09-12 2023-03-10 제넨테크, 인크. 항-her2 항체 및 면역콘주게이트
CA2983459C (en) 2014-10-16 2023-11-07 The University Of Melbourne Imaging composition and uses thereof
EA037590B1 (ru) 2014-11-25 2021-04-19 Бристол-Майерс Сквибб Компани Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
WO2016144873A2 (en) 2015-03-06 2016-09-15 Mayo Foundation For Medical Education And Research Methods for cell labeling and medical imaging
NL2014423B1 (en) 2015-03-09 2016-10-13 Linxis B V Method for removing weakly bound functional moieties from cell targeting conjugates.
WO2016172010A1 (en) 2015-04-20 2016-10-27 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
CN106699888B (zh) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
US20170097333A1 (en) 2015-09-28 2017-04-06 Merck Sharp & Dohme Corp. Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
EP3359573B1 (en) 2015-10-01 2023-01-04 The Whitehead Institute for Biomedical Research Labeling of antibodies
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
EP3377117A1 (en) 2015-11-18 2018-09-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
US20190330336A1 (en) 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
KR20180086502A (ko) 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항원-결합 단편
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
IL262892B2 (en) 2016-05-18 2024-04-01 Boehringer Ingelheim Int Anti pd-1 and anti-lag3 antibodies for cancer treatment
HRP20210644T8 (hr) 2016-05-19 2021-06-25 Bristol-Myers Squibb Company Imunomodulatori za pet-snimanje
AU2017278573A1 (en) 2016-06-06 2019-01-03 Linxis B.V. Cell targeting conjugates
SI3472207T1 (sl) 2016-06-20 2021-04-30 F-Star Delta Limited Vezavne molekule, ki vežejo PD-L1 in LAG-3
PT3476399T (pt) 2016-06-23 2022-05-31 Jiangsu Hengrui Medicine Co Anticorpo lag-3, fragmento de ligação a antigénio deste e aplicação farmacêutica deste
EP3474879A4 (en) 2016-06-24 2020-05-06 University of Iowa Research Foundation Compositions and methods of treating melanoma
EP3266465A1 (en) 2016-07-06 2018-01-10 Julius-Maximilians-Universität Würzburg Immune complexes
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
CA3031076C (en) 2016-07-18 2023-10-03 Wisconsin Alumni Research Foundation Radiohalogenated agents for in situ immune modulated cancer vaccination
EP3510046A4 (en) 2016-09-07 2020-05-06 The Regents of the University of California ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
PL3515946T3 (pl) * 2016-09-23 2022-11-07 Regeneron Pharmaceuticals, Inc. Przeciwciała anty-muc16 (mucyna 16)
EP4026849A1 (en) 2016-09-26 2022-07-13 Ensemble Group Holdings Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems using a combination of vegfr-3 and pd-1 or pd-l1 inhibitors
WO2018128664A2 (en) 2016-10-20 2018-07-12 The University Of North Carolina At Chapel Hill 18f-labeled compounds for pet imaging and uses thereof
EP4464334A3 (en) 2016-11-07 2025-01-08 VIDAC Pharma Ltd. Use of compounds for treating hk2-expressing cancers
CN110382534B (zh) * 2016-11-29 2023-05-09 里珍纳龙药品有限公司 治疗prlr阳性乳腺癌的方法
US10736976B2 (en) * 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
CN110168105B (zh) 2016-12-09 2024-05-24 瑞泽恩制药公司 用于对t细胞受体进行测序的系统和方法及其用途
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
SG11202002282TA (en) 2017-09-20 2020-04-29 Regeneron Pharma Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eur J Nucl Med Mol Imaging，2010年，vol.37，p.250-259
Expert Opin. Ther. Targets，2011年，vol.15, no.1，p.91-101

Also Published As

Publication number Publication date
MA47456A (fr) 2019-12-18
EP3580238A1 (en) 2019-12-18
MX2019009565A (es) 2020-02-24
CN110650974A (zh) 2020-01-03
IL313695A (en) 2024-08-01
US20180228926A1 (en) 2018-08-16
SG11201907208XA (en) 2019-09-27
IL268667B2 (en) 2024-12-01
KR102660715B1 (ko) 2024-04-26
US20210138096A1 (en) 2021-05-13
PH12019501837A1 (en) 2020-06-15
KR20190123738A (ko) 2019-11-01
US10905784B2 (en) 2021-02-02
AU2025200923A1 (en) 2025-03-20
EA201991673A1 (ru) 2020-01-17
MA46814B2 (fr) 2022-09-30
MX2025004620A (es) 2025-06-02
BR112019016336A2 (pt) 2020-03-31
IL268667A (en) 2019-10-31
AU2018219909B2 (en) 2025-02-27
MA46814A1 (fr) 2021-04-30
MY200034A (en) 2023-12-05
IL268667B1 (en) 2024-08-01
KR102813603B1 (ko) 2025-05-29
US20230270894A1 (en) 2023-08-31
KR20240058959A (ko) 2024-05-07
WO2018148476A1 (en) 2018-08-16
JP2020507571A (ja) 2020-03-12
CN110650974B (zh) 2024-04-19
CL2019002264A1 (es) 2020-01-10
US11511001B2 (en) 2022-11-29
CA3053348A1 (en) 2018-08-16
CN118557758A (zh) 2024-08-30
CO2019008675A2 (es) 2019-10-31
AU2018219909A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
JP7167041B2 (ja) 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体
US12053534B2 (en) Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
US12077587B2 (en) Anti-CD8 antibodies and uses thereof
EP4665410A1 (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
EA043673B1 (ru) Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
EA044824B1 (ru) Антитела к cd8 и пути их применения
BR122025021510A2 (pt) Anticorpo monoclonal isolado ou fragmento de ligação a antígeno deste que se liga a cd8, uso do mesmo, célula hospedeira, composição farmacêutica, molécula de ácido nucleico, vetor de expressão, composto, conjugado de anticorpo, e, método para gerar imagens de um tecido que expressa cd8

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221026

R150 Certificate of patent or registration of utility model

Ref document number: 7167041

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150